Literature DB >> 2120019

Duodenal pH in cystic fibrosis and its relationship to fat malabsorption.

P J Robinson1, A L Smith, P D Sly.   

Abstract

To investigate the relationship between duodenal pH levels and supplemental pancreatic enzyme function in cystic fibrosis, 18 children with this condition had pH recordings performed from the second and fourth part of the duodenum. Compared to age-matched controls, patients with cystic fibrosis had significantly longer periods below a pH of 4.0 in the postprandial period and significantly less time above pH 5.8. These values correspond to the pH levels at which lipase is irreversibly destroyed (pH 4.0) and enteric coating of enzyme supplements dissolves (pH 5.8). A significant relationship was found between the pH recordings from the fourth part of the duodenum and the degree of residual fat malabsorption while taking enteric-coated enzyme supplements. Four patients with an excessively acidic duodenum and residual fat malabsorption despite high-dose enzyme supplementation were treated with misoprostol (Searle), a known acid-reducing agent. There were significant improvements in both duodenal pH values and fat absorption. We conclude that there is a wide range of duodenal pH values found in patients with cystic fibrosis and that the efficiency with which enzyme supplements work is closely related to these pH levels. Administration of misoprostol to those patients with excessively acidic duodenal pH levels as well as residual malabsorption appears to be of benefit in improving both the excessively acidic pH levels and the fat malabsorption.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120019     DOI: 10.1007/bf01536423

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  8 in total

1.  High compared with standard dose lipase pancreatic supplement.

Authors:  P J Robinson; A Olinsky; A L Smith; S B Chitravanshi
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

2.  Rapid method for the determination of fat in feces.

Authors:  J H VAN DE KAMER; H TEN BOKKEL HUININK; H A WEYERS
Journal:  J Biol Chem       Date:  1949-01       Impact factor: 5.157

3.  Intraduodenal events in cystic fibrosis.

Authors:  A M Weber; C C Roy
Journal:  J Pediatr Gastroenterol Nutr       Date:  1984       Impact factor: 2.839

4.  Long-term cimetidine in children with cystic fibrosis: a randomized double-blind study.

Authors:  M Schöni; R Kraemer; A Ruedeberg; M J Lentze; R C Mordasini; W F Riesen; M P Kläy; E Rossi
Journal:  Pediatr Res       Date:  1984-01       Impact factor: 3.756

5.  Effect of misoprostol on fat malabsorption in cystic fibrosis.

Authors:  P J Robinson; P D Sly; A L Smith
Journal:  Arch Dis Child       Date:  1988-09       Impact factor: 3.791

6.  Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis.

Authors:  P R Durie; L Bell; W Linton; M L Corey; G G Forstner
Journal:  Gut       Date:  1980-09       Impact factor: 23.059

7.  Gastric acid hypersecretion in cystic fibrosis.

Authors:  K L Cox; J N Isenberg; M E Ament
Journal:  J Pediatr Gastroenterol Nutr       Date:  1982       Impact factor: 2.839

8.  Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects.

Authors:  C A Youngberg; R R Berardi; W F Howatt; M L Hyneck; G L Amidon; J H Meyer; J B Dressman
Journal:  Dig Dis Sci       Date:  1987-05       Impact factor: 3.199

  8 in total
  18 in total

Review 1.  Control of malabsorption in cystic fibrosis.

Authors:  J M Littlewood; S P Wolfe
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 3.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 4.  Review of paediatric gastrointestinal physiology data relevant to oral drug delivery.

Authors:  Jonathan L Kaye
Journal:  Int J Clin Pharm       Date:  2011-01-12

5.  Is fibrosing colonopathy an immune mediated disease?

Authors:  J Lee; W Ip; P Durie
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

6.  In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.

Authors:  Robert J Kuhn; Sabine Eyting; Friederike Henniges; Andreas Potthoff
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

7.  Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility.

Authors:  Anil R Maharaj; Andrea N Edginton; Nikoletta Fotaki
Journal:  Pharm Res       Date:  2015-07-29       Impact factor: 4.200

8.  Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.

Authors:  Marijke Proesmans; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2003-09-17       Impact factor: 3.183

Review 9.  The cystic fibrosis of exocrine pancreas.

Authors:  Michael Wilschanski; Ivana Novak
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

10.  Cellular chloride and bicarbonate retention alters intracellular pH regulation in Cftr KO crypt epithelium.

Authors:  Nancy M Walker; Jinghua Liu; Sydney R Stein; Casey D Stefanski; Ashlee M Strubberg; Lane L Clarke
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-05       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.